Trial Profile
A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms MAVERIC
- 27 Mar 2019 Status changed from recruiting to completed.
- 10 Jul 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 10 Jul 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.